Form 4: Avid Bioservices Executive Matthew Kwietniak Reports Stock Unit Transactions

Sentiment:

SEC Form 4 Filing


Chief Commercial Officer Matthew Kwietniak reports transactions involving restricted stock units of Avid Bioservices, Inc.

Summary

  • On April 9, 2024, Matthew R. Kwietniak, Chief Commercial Officer of Avid Bioservices, Inc., reported transactions involving the vesting of restricted stock units (RSUs).
  • Kwietniak vested 1,261 RSUs and 1,271 RSUs, which converted into common stock.
  • Following these transactions, Kwietniak directly owns 21,090 and 22,361 shares of common stock, respectively.
  • He also holds 33,836 and 32,565 RSUs.

Sentiment

Score: 5

Explanation: This is a neutral disclosure of stock transactions, neither particularly positive nor negative.

Industry Context

This filing is a routine disclosure of insider transactions, common for publicly traded companies. It provides transparency into the trading activities of company executives.

Stakeholder Impact

  • The transactions have a minor dilutive effect on existing shareholders due to the issuance of new shares upon RSU vesting.

Key Dates

DateDescription
July 9, 2022Date of grant for 1,261 RSUs vesting quarterly over four years.
October 9, 2022Vesting start date for RSUs granted on July 9, 2022.
July 9, 2023Date of grant for 1,271 RSUs vesting quarterly over four years.
October 9, 2023Vesting start date for RSUs granted on July 9, 2023.
April 9, 2024Date of RSU transactions.
April 11, 2024Date of Form 4 filing.

Keywords

Avid Bioservices, CDMO, Matthew Kwietniak, Restricted Stock Units, RSU, Form 4, Insider Trading, Beneficial Ownership, Securities, Stock Options

Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.